Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tadalafil 5 mg Clear all
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

NCT01484431
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil- Tablet or Oral suspension
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00384930
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 22, 2026, 2:21 PM EDT
Not yet recruiting Phase 2 Interventional

Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment

NCT07882901
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Tadalafil 5 mg
Drug
Lead sponsor
Los Angeles Brain Science Project
Other
Eligibility
60 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems

NCT00547625
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostate
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

NCT00422734
View directory record Official record
Conditions
Impotence
Interventions
tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Oct 22, 2026, 2:21 PM EDT
Withdrawn Phase 3 Interventional

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage

NCT01960153
View directory record Official record
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

NCT01042158
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
Interventions
tadalafil and ambrisentan upfront combination therapy
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study in Erectile Dysfunction

NCT00833638
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Placebo, Tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of Tadalafil and Glycemic Traits

NCT01444651
View directory record Official record
Conditions
Cardiovascular Disease, Insulin Resistance, Glucose Intolerance, Obesity
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Thomas J. Wang, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY900010 in Erectile Dysfunction

NCT01160289
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
LY2452473, tadalafil, placebo (tadalafil), placebo (LY2452473)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 70 Years · Male only
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Glendora, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months

NCT00333281
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 25, 2007 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

NCT00827242
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo, tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Huntsville, Alabama • Middlebury, Connecticut • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2623091 in Healthy Participants

NCT02300259
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2623091, Itraconazole, Simvastatin, Tadalafil, Diltiazem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction

NCT00381732
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2007 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

NCT00125918
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Tucson, Arizona • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Study in Benign Prostatic Hyperplasia

NCT01152190
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Garden City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

NCT00848081
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
28
States / cities
Huntsville, Alabama • Anchorage, Alaska • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)

NCT02058095
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 22, 2026, 2:21 PM EDT
Not listed Phase 4 Interventional

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

NCT02225548
View directory record Official record
Conditions
Parkinson's Disease, Erectile Dysfunction
Interventions
Selegiline, Tadalafil
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 64 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Tadalafil, Placebo, Finasteride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Davis, California • Fresno, California • Laguna Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

NCT04984993
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
MED3000 (Male), Tadalafil 5mg (Male), MED3000 (Female), Tadalafil 5mg (Female)
Device · Drug
Lead sponsor
Futura Medical Developments Ltd.
Industry
Eligibility
22 Years to 70 Years · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Actual Use Trial of Tadalafil 5 mg

NCT06805513
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tadalafil 5 mg tablets with a digital tool.
Combination Product
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 2:21 PM EDT